Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation (CDMO), and NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy, today announced ...

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

The development of efficient and safe delivery systems is a cornerstone of gene therapy and genome editing. Lipid nanoparticles (LNPs), adeno-associated ...

Viral vectors are key delivery tools for advanced therapies, enabling gene transfer to treat inherited disorders, cancer and other serious diseases. Despite rapid clinical progress, manufacturing ...

Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or ...

UK-based gene therapy CDMO embeds NanoMosaic's Tessie platform across its AAV development and manufacturing services. Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation ...

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...

Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...

AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...

Forge’s FUEL™ platform and manufacturing services support the production of AAV for EPI-321, Epicrispr’s investigational gene therapy for FSHD Material manufactured at Forge for Epicrispr is being ...

Viralgen continues its pioneering work in manufacturing science with advancements in key process understanding with analytical tools ...